The global Meningococcal Vaccine market was valued at 230.87 Million USD in 2020 and will grow with a CAGR of 4.33% from 2020 to 2027, based on newly published report.

The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

By Market Verdors:

Novartis

GSK

Merck

CSL

Baxter

JN International Medical Corporation

Serum Institute of India

Bio-Med

China National Biotec Group

Hualan Bio

Walvax

Zhifei

By Types:

Quadrivalent

Bivalent

By Applications:

Pneumonia

Meningitis

Bacteremia

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.

Market Trends: Market key trends which include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Meningococcal Vaccine Revenue

1.4 Market Analysis by Type

1.4.1 Global Meningococcal Vaccine Market Size Growth Rate by Type: 2021 VS 2027

1.4.2 Quadrivalent

1.4.3 Bivalent

1.5 Market by Application

1.5.1 Global Meningococcal Vaccine Market Share by Application: 2022-2027

1.5.2 Pneumonia

1.5.3 Meningitis

1.5.4 Bacteremia

1.6 Study Objectives

1.7 Years Considered

1.8 Overview of Global Meningococcal Vaccine Market

1.8.1 Global Meningococcal Vaccine Market Status and Outlook (2016-2027)

1.8.2 North America

1.8.3 East Asia

1.8.4 Europe

1.8.5 South Asia

1.8.6 Southeast Asia

1.8.7 Middle East

1.8.8 Africa

1.8.9 Oceania

1.8.10 South America

1.8.11 Rest of the World

2 Market Competition by Manufacturers

2.1 Global Meningococcal Vaccine Production Capacity Market Share by Manufacturers (2016-2021)

2.2 Global Meningococcal Vaccine Revenue Market Share by Manufacturers (2016-2021)

2.3 Global Meningococcal Vaccine Average Price by Manufacturers (2016-2021)

2.4 Manufacturers Meningococcal Vaccine Production Sites, Area Served, Product Type

3 Sales by Region

3.1 Global Meningococcal Vaccine Sales Volume Market Share by Region (2016-2021)

3.2 Global Meningococcal Vaccine Sales Revenue Market Share by Region (2016-2021)

3.3 North America Meningococcal Vaccine Sales Volume

3.3.1 North America Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.3.2 North America Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.4 East Asia Meningococcal Vaccine Sales Volume

3.4.1 East Asia Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.4.2 East Asia Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.5 Europe Meningococcal Vaccine Sales Volume (2016-2021)

3.5.1 Europe Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.5.2 Europe Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.6 South Asia Meningococcal Vaccine Sales Volume (2016-2021)

3.6.1 South Asia Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.6.2 South Asia Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.7 Southeast Asia Meningococcal Vaccine Sales Volume (2016-2021)

3.7.1 Southeast Asia Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.7.2 Southeast Asia Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.8 Middle East Meningococcal Vaccine Sales Volume (2016-2021)

3.8.1 Middle East Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.8.2 Middle East Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.9 Africa Meningococcal Vaccine Sales Volume (2016-2021)

3.9.1 Africa Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.9.2 Africa Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.10 Oceania Meningococcal Vaccine Sales Volume (2016-2021)

3.10.1 Oceania Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.10.2 Oceania Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.11 South America Meningococcal Vaccine Sales Volume (2016-2021)

3.11.1 South America Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.11.2 South America Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.12 Rest of the World Meningococcal Vaccine Sales Volume (2016-2021)

3.12.1 Rest of the World Meningococcal Vaccine Sales Volume Growth Rate (2016-2021)

3.12.2 Rest of the World Meningococcal Vaccine Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

4 North America

4.1 North America Meningococcal Vaccine Consumption by Countries

4.2 United States

4.3 Canada

4.4 Mexico

5 East Asia

5.1 East Asia Meningococcal Vaccine Consumption by Countries

5.2 China

5.3 Japan

5.4 South Korea

6 Europe

6.1 Europe Meningococcal Vaccine Consumption by Countries

6.2 Germany

6.3 United Kingdom

6.4 France

6.5 Italy

6.6 Russia

6.7 Spain

6.8 Netherlands

6.9 Switzerland

6.10 Poland

7 South Asia

7.1 South Asia Meningococcal Vaccine Consumption by Countries

7.2 India

7.3 Pakistan

7.4 Bangladesh

8 Southeast Asia

8.1 Southeast Asia Meningococcal Vaccine Consumption by Countries

8.2 Indonesia

8.3 Thailand

8.4 Singapore

8.5 Malaysia

8.6 Philippines

8.7 Vietnam

8.8 Myanmar

9 Middle East

9.1 Middle East Meningococcal Vaccine Consumption by Countries

9.2 Turkey

9.3 Saudi Arabia

9.4 Iran

9.5 United Arab Emirates

9.6 Israel

9.7 Iraq

9.8 Qatar

9.9 Kuwait

9.10 Oman

10 Africa

10.1 Africa Meningococcal Vaccine Consumption by Countries

10.2 Nigeria

10.3 South Africa

10.4 Egypt

10.5 Algeria

10.6 Morocco

11 Oceania

11.1 Oceania Meningococcal Vaccine Consumption by Countries

11.2 Australia

11.3 New Zealand

12 South America

12.1 South America Meningococcal Vaccine Consumption by Countries

12.2 Brazil

12.3 Argentina

12.4 Columbia

12.5 Chile

12.6 Venezuela

12.7 Peru

12.8 Puerto Rico

12.9 Ecuador

13 Rest of the World

13.1 Rest of the World Meningococcal Vaccine Consumption by Countries

13.2 Kazakhstan

14 Sales Volume, Sales Revenue, Sales Price Trend by Type

14.1 Global Meningococcal Vaccine Sales Volume Market Share by Type (2016-2021)

14.2 Global Meningococcal Vaccine Sales Revenue Market Share by Type (2016-2021)

14.3 Global Meningococcal Vaccine Sales Price by Type (2016-2021)

15 Consumption Analysis by Application

15.1 Global Meningococcal Vaccine Consumption Volume by Application (2016-2021)

15.2 Global Meningococcal Vaccine Consumption Value by Application (2016-2021)

16 Company Profiles and Key Figures in Meningococcal Vaccine Business

16.1 Novartis

16.1.1 Novartis Company Profile

16.1.2 Novartis Meningococcal Vaccine Product Specification

16.1.3 Novartis Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.2 GSK

16.2.1 GSK Company Profile

16.2.2 GSK Meningococcal Vaccine Product Specification

16.2.3 GSK Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.3 Merck

16.3.1 Merck Company Profile

16.3.2 Merck Meningococcal Vaccine Product Specification

16.3.3 Merck Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.4 CSL

16.4.1 CSL Company Profile

16.4.2 CSL Meningococcal Vaccine Product Specification

16.4.3 CSL Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.5 Baxter

16.5.1 Baxter Company Profile

16.5.2 Baxter Meningococcal Vaccine Product Specification

16.5.3 Baxter Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.6 JN International Medical Corporation

16.6.1 JN International Medical Corporation Company Profile

16.6.2 JN International Medical Corporation Meningococcal Vaccine Product Specification

16.6.3 JN International Medical Corporation Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.7 Serum Institute of India

16.7.1 Serum Institute of India Company Profile

16.7.2 Serum Institute of India Meningococcal Vaccine Product Specification

16.7.3 Serum Institute of India Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.8 Bio-Med

16.8.1 Bio-Med Company Profile

16.8.2 Bio-Med Meningococcal Vaccine Product Specification

16.8.3 Bio-Med Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.9 China National Biotec Group

16.9.1 China National Biotec Group Company Profile

16.9.2 China National Biotec Group Meningococcal Vaccine Product Specification

16.9.3 China National Biotec Group Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.10 Hualan Bio

16.10.1 Hualan Bio Company Profile

16.10.2 Hualan Bio Meningococcal Vaccine Product Specification

16.10.3 Hualan Bio Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.11 Walvax

16.11.1 Walvax Company Profile

16.11.2 Walvax Meningococcal Vaccine Product Specification

16.11.3 Walvax Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.12 Zhifei

16.12.1 Zhifei Company Profile

16.12.2 Zhifei Meningococcal Vaccine Product Specification

16.12.3 Zhifei Meningococcal Vaccine Production Capacity, Revenue, Price and Gross Margin (2016-2021)

17 Meningococcal Vaccine Manufacturing Cost Analysis

17.1 Meningococcal Vaccine Key Raw Materials Analysis

17.1.1 Key Raw Materials

17.2 Proportion of Manufacturing Cost Structure

17.3 Manufacturing Process Analysis of Meningococcal Vaccine

17.4 Meningococcal Vaccine Industrial Chain Analysis

18 Marketing Channel, Distributors and Customers

18.1 Marketing Channel

18.2 Meningococcal Vaccine Distributors List

18.3 Meningococcal Vaccine Customers

19 Market Dynamics

19.1 Market Trends

19.2 Opportunities and Drivers

19.3 Challenges

19.4 Porter's Five Forces Analysis

20 Production and Supply Forecast

20.1 Global Forecasted Production of Meningococcal Vaccine (2022-2027)

20.2 Global Forecasted Revenue of Meningococcal Vaccine (2022-2027)

20.3 Global Forecasted Price of Meningococcal Vaccine (2016-2027)

20.4 Global Forecasted Production of Meningococcal Vaccine by Region (2022-2027)

20.4.1 North America Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.2 East Asia Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.3 Europe Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.4 South Asia Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.5 Southeast Asia Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.6 Middle East Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.7 Africa Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.8 Oceania Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.9 South America Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.4.10 Rest of the World Meningococcal Vaccine Production, Revenue Forecast (2022-2027)

20.5 Forecast by Type and by Application (2022-2027)

20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)

20.5.2 Global Forecasted Consumption of Meningococcal Vaccine by Application (2022-2027)

21 Consumption and Demand Forecast

21.1 North America Forecasted Consumption of Meningococcal Vaccine by Country

21.2 East Asia Market Forecasted Consumption of Meningococcal Vaccine by Country

21.3 Europe Market Forecasted Consumption of Meningococcal Vaccine by Countriy

21.4 South Asia Forecasted Consumption of Meningococcal Vaccine by Country

21.5 Southeast Asia Forecasted Consumption of Meningococcal Vaccine by Country

21.6 Middle East Forecasted Consumption of Meningococcal Vaccine by Country

21.7 Africa Forecasted Consumption of Meningococcal Vaccine by Country

21.8 Oceania Forecasted Consumption of Meningococcal Vaccine by Country

21.9 South America Forecasted Consumption of Meningococcal Vaccine by Country

21.10 Rest of the world Forecasted Consumption of Meningococcal Vaccine by Country

22 Research Findings and Conclusion

23 Methodology and Data Source

23.1 Methodology/Research Approach

23.1.1 Research Programs/Design

23.1.2 Market Size Estimation

23.1.3 Market Breakdown and Data Triangulation

23.2 Data Source

23.2.1 Secondary Sources

23.2.2 Primary Sources

23.3 Disclaimer

Methodology/Research Approach

Research Programs/Design

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources